TY - JOUR
T1 - Effect of Tricuspid Regurgitation on the Reported Quality of Life and Subsequent Outcomes in Patients With Atrial Fibrillation
AU - Fujisawa, Taishi
AU - Kimura, Takehiro
AU - Ikemura, Nobuhiro
AU - Miyama, Hiroshi
AU - Katsumata, Yoshinori
AU - Ueda, Ikuko
AU - Tanimoto, Kojiro
AU - Kanki, Hideaki
AU - Fukuda, Keiichi
AU - Kohsaka, Shun
AU - Takatsuki, Seiji
N1 - Funding Information:
Dr Kohsaka received an unrestricted research grant for the Department of Cardiology at Keio University School of Medicine from Bayer, Daiichi Sankyo and Novartis, and honoria from Bristol Myers Squibb and Pfizer. Dr Takatsuki
Publisher Copyright:
© 2022, American Heart Association Inc. All rights reserved.
PY - 2022/4/19
Y1 - 2022/4/19
N2 - BACKGROUND: Atrial fibrillation and heart failure (HF) possess mutual risk factors and share a common pathophysiological pathway. Tricuspid regurgitation (TR) is a known predictor of adverse events in patients with HF. However, its implications on patients with atrial fibrillation in its early stage remain unknown. METHODS AND RESULTS: Data of 2211 patients without previous HF diagnosis were extracted from a prospective, multicenter registry of newly diagnosed patients with atrial fibrillation. TR was categorized as absent, mild, moderate, and severe based on the American Society of Echocardiography recommendations. The primary outcome was time to first hospitalization for HF after enrollment. The Atrial Fibrillation Effects on Quality-of-Life scores were compared. Overall, 1107 patients (50.1%) had TR (42.3%, 7.2%, and 0.6% for mild, moderate, and severe, respectively). During follow-up (median 730 [interquartile range, 366–731] days), 44 patients (2.0%) expe-rienced HF hospitalization, and the incidence increased with severity of TR (P<0.001). TR was an associated predictor of the primary outcome (hazard ratio [HR]: 2.51, P=0.050; HR: 6.19, P=0.008; for moderate and severe TR versus no TR). Changes in AFEQT overall score were negatively related to TR severity (8.7±17.5 versus 8.5±17.0 versus 3.1±17.5 versus 1.4±11.8, absent versus mild versus moderate versus severe TR, respectively), although it was not an independent predictor after adjustments. CONCLUSIONS: TR severity at atrial fibrillation diagnosis was an associated predictor of subsequent hospitalization for HF, which may warrant the need for a more intensive follow-up and HF-related management.
AB - BACKGROUND: Atrial fibrillation and heart failure (HF) possess mutual risk factors and share a common pathophysiological pathway. Tricuspid regurgitation (TR) is a known predictor of adverse events in patients with HF. However, its implications on patients with atrial fibrillation in its early stage remain unknown. METHODS AND RESULTS: Data of 2211 patients without previous HF diagnosis were extracted from a prospective, multicenter registry of newly diagnosed patients with atrial fibrillation. TR was categorized as absent, mild, moderate, and severe based on the American Society of Echocardiography recommendations. The primary outcome was time to first hospitalization for HF after enrollment. The Atrial Fibrillation Effects on Quality-of-Life scores were compared. Overall, 1107 patients (50.1%) had TR (42.3%, 7.2%, and 0.6% for mild, moderate, and severe, respectively). During follow-up (median 730 [interquartile range, 366–731] days), 44 patients (2.0%) expe-rienced HF hospitalization, and the incidence increased with severity of TR (P<0.001). TR was an associated predictor of the primary outcome (hazard ratio [HR]: 2.51, P=0.050; HR: 6.19, P=0.008; for moderate and severe TR versus no TR). Changes in AFEQT overall score were negatively related to TR severity (8.7±17.5 versus 8.5±17.0 versus 3.1±17.5 versus 1.4±11.8, absent versus mild versus moderate versus severe TR, respectively), although it was not an independent predictor after adjustments. CONCLUSIONS: TR severity at atrial fibrillation diagnosis was an associated predictor of subsequent hospitalization for HF, which may warrant the need for a more intensive follow-up and HF-related management.
KW - atrial fibrillation
KW - heart failure
KW - quality of life
KW - tricuspid regurgitation
UR - http://www.scopus.com/inward/record.url?scp=85128797911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128797911&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.022713
DO - 10.1161/JAHA.121.022713
M3 - Article
C2 - 35383465
AN - SCOPUS:85128797911
SN - 2047-9980
VL - 11
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 8
M1 - e022713
ER -